Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1691
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18256997 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | Non-Final OA | Merck Sharp & Dohme LLC |
| 17775100 | EFFECTIVE INTRANASAL DELIVERY TO BRAIN | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18274560 | METHODS FOR INHIBITING CORONAVIRUSES USING SULFORAPHANE | Non-Final OA | The Johns Hopkins University |
| 18145595 | UREA INHIBITORS OF MICRO-RNA | Final Rejection | Board of Regents, The University of Texas System |
| 18007822 | METHODS OF TREATING A CORONAVIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 18329586 | METHOD OF SCREENING FOR DRUG COMBINATION FOR COLORECTAL CARCINOMA TREATMENT, DRUG COMBINATION AND USE THEREOF | Non-Final OA | National Tsing Hua University |
| 18288131 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | Non-Final OA | Kyoto University |
| 18026397 | METHODS OF TREATING AND/OR PREVENTING ALZHEIMER’S DISEASE WITH R-CARVEDILOL | Non-Final OA | UTI LIMITED PARTNERSHIP |
| 18565082 | COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION AND RELATED DISEASES, DISORDERS, AND CONDITIONS | Non-Final OA | Adamo Bioscience, Inc. |
| 18245217 | COMPOSITIONS AND METHODS FOR INHIBITING TREM-1 | Non-Final OA | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. |
| 17921614 | COMBINATION OF BCMA-DIRECTED T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Final Rejection | Juno Therapeutics, Inc. |
| 18336117 | KAT6 TARGETING COMPOUNDS | Non-Final OA | Prelude Therapeutics Incorporated |
| 17923803 | METHODS OF MONITORING KRAS MUTATIONS | Non-Final OA | Cardiff Oncology, Inc. |
| 18302738 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | Non-Final OA | FRONTIER MEDICINES CORPORATION |
| 17909307 | PHARMACEUTICAL COMPOSITIONS COMPRISING DASATINIB ANHYDROUS AND USES THEREOF | Non-Final OA | ZENTIVA K.S. |
| 18105460 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | Non-Final OA | Ascendis Pharma A/S |
| 17926104 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | Non-Final OA | Qx Therapeutics Inc. |
| 17920226 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | Non-Final OA | C4X Discovery Limited |
| 17916702 | Use of Mitochondria-Targeted Antioxidants to Treat Severe Inflammatory Conditions | Non-Final OA | Mitotech S.A. |
| 17915326 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Non-Final OA | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. |
| 17904636 | OLAPARIB PHARMACEUTICAL COMPOSITION, FORMULATION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Non-Final OA | Sinotherapeutics Inc. |
| 17756899 | COMPOSITION AND METHOD FOR TREATING CANCER | Non-Final OA | Carmel-Haifa University Economic Corp Ltd. |
| 17778664 | Methods for Treating Coronavirus Infections | Final Rejection | GUANGZHOU HEALTHQUEST PHARMA CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy